ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 133 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q1 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,017,530 | +37.9% | 78,964 | +54.8% | 0.00% | – |
| Q2 2023 | $1,463,254 | +23.8% | 51,020 | +3.5% | 0.00% | – |
| Q1 2023 | $1,182,152 | -18.3% | 49,318 | -42.2% | 0.00% | -100.0% |
| Q4 2022 | $1,447,401 | +214.0% | 85,342 | +174.8% | 0.00% | – |
| Q3 2022 | $461,000 | -20.7% | 31,052 | -15.9% | 0.00% | – |
| Q2 2022 | $581,000 | -86.2% | 36,928 | -76.4% | 0.00% | -100.0% |
| Q1 2022 | $4,225,000 | -46.7% | 156,709 | -26.8% | 0.00% | -66.7% |
| Q4 2021 | $7,926,000 | -28.1% | 214,153 | -7.2% | 0.00% | -25.0% |
| Q3 2021 | $11,028,000 | +242.5% | 230,798 | +142.6% | 0.00% | +300.0% |
| Q2 2021 | $3,220,000 | -56.2% | 95,150 | -46.6% | 0.00% | -66.7% |
| Q1 2021 | $7,356,000 | -57.6% | 178,100 | -55.5% | 0.00% | -66.7% |
| Q4 2020 | $17,366,000 | +49.1% | 400,326 | +47.5% | 0.01% | +28.6% |
| Q3 2020 | $11,646,000 | +13.4% | 271,456 | +23.5% | 0.01% | 0.0% |
| Q2 2020 | $10,273,000 | +4025.7% | 219,788 | +1099.3% | 0.01% | – |
| Q1 2020 | $249,000 | – | 18,327 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |